{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent+2&page=2",
    "query": {
      "intervention": "Combination Agent 2",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent+2&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T12:47:37.478Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00002235",
      "title": "A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Indinavir sulfate",
          "type": "DRUG"
        },
        {
          "name": "Nelfinavir mesylate",
          "type": "DRUG"
        },
        {
          "name": "Efavirenz",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 6,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-09-27T12:47:37.478Z",
      "location_count": 5,
      "location_summary": "Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Hampton",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002235"
    },
    {
      "nct_id": "NCT04742634",
      "title": "Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "DEC-C",
          "type": "DRUG"
        },
        {
          "name": "MyeloSeq-HD",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 209,
      "start_date": "2022-05-12",
      "completion_date": "2033-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-09-27T12:47:37.478Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04742634"
    },
    {
      "nct_id": "NCT07214987",
      "title": "PDT For Induction Therapy For Head And Neck Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma",
        "Head and Neck Cancer Squamous Cell Carcinoma",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Toripalimab-tpzi",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2026-03-09",
      "completion_date": "2029-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-09-27T12:47:37.478Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07214987"
    },
    {
      "nct_id": "NCT06203821",
      "title": "Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "NP137",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aram Hezel",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2026-09-01",
      "completion_date": "2032-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-09-27T12:47:37.478Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06203821"
    },
    {
      "nct_id": "NCT07423078",
      "title": "Window of Opportunity in Preserving Laryngeal Function Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)",
        "Locally Advanced Laryngeal Squamous Cell Carcinoma",
        "Hypopharyngeal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Toripalimab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Matthew Spector",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2026-04-06",
      "completion_date": "2031-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-09-27T12:47:37.478Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07423078"
    },
    {
      "nct_id": "NCT06191978",
      "title": "A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "ASTX727",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 40,
      "start_date": "2024-03-07",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-09-27T12:47:37.478Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06191978"
    },
    {
      "nct_id": "NCT00654147",
      "title": "Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Raltegravir & Lopinavir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Raltegravir and emtricitabine/tenofovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Margaret A. Fischl, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2008-04",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2015-08-03",
      "last_synced_at": "2026-09-27T12:47:37.478Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00654147"
    },
    {
      "nct_id": "NCT06357858",
      "title": "ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Squamous Cell Carcinoma of the Head and Neck",
        "Metastatic Squamous Cell Carcinoma",
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "INQOVI (decitabine and cedazuridine)",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-06-01",
      "completion_date": "2026-02-28",
      "has_results": false,
      "last_update_posted_date": "2024-07-03",
      "last_synced_at": "2026-09-27T12:47:37.478Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06357858"
    },
    {
      "nct_id": "NCT04553263",
      "title": "Relapse Prevention in Stimulant Use Disorder",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Stimulant Use",
        "Relapse",
        "Cognitive Function",
        "ADHD"
      ],
      "interventions": [
        {
          "name": "Contrave 8Mg-90Mg Extended-Release Tablet",
          "type": "DRUG"
        },
        {
          "name": "Bupropion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-06-11",
      "completion_date": "2025-01-11",
      "has_results": false,
      "last_update_posted_date": "2023-09-22",
      "last_synced_at": "2026-09-27T12:47:37.478Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04553263"
    },
    {
      "nct_id": "NCT03106948",
      "title": "Delivery of Inhibitors of Lysyl Oxidase (LysoLox) on Serial Angioplasty and Time to Restenosis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Arteriovenous Fistula Occlusion"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ascorbic Acid",
          "type": "DRUG"
        },
        {
          "name": "Cuprimine Oral Product",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southeast Renal Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 30,
      "start_date": "2017-02-01",
      "completion_date": "2018-03",
      "has_results": false,
      "last_update_posted_date": "2017-09-11",
      "last_synced_at": "2026-09-27T12:47:37.478Z",
      "location_count": 1,
      "location_summary": "Chattanooga, Tennessee",
      "locations": [
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03106948"
    }
  ]
}